Everyday EBM
Everyday EBM - July 22, 2015 - By Kroll M - Faculty Reviewed by Panagos P
"Clinical question: Does TXA improve outcomes for patients with spontaneous subarachnoid hemorrhage? Does it increase the risk for thrombotic event/stroke?
Take home: TXA may reduce the risk of rebleeding in aneurysmal subarachnoid hemorrhage, but current evidence does not strongly support a benefit regarding survival or morbidity. In studies using prolonged anti-fibrinolytic therapy, thebenefit conferred by decreased risk of rebleed was offset by increase in cerebral ischemia. However, more recent trials of short-term antifibrinolytic therapy have had promising, but far from definitive results. Current AHA/ASA guidelines encourage its use for patients who will have a delay in aneurysm obliteration."
http://wueverydayebm.blogspot.com.es/2015/07/if-theres-delay-consider-txa-on-anti.html